news.med.miami.edu
Jun 16, 2025, 02:06
C. Ola Landgren: Presenting ADVANCE Trial Results in Multiple Myeloma at EHA25
C. Ola Landgren, Leader, Translational and Clinical Oncology Program/Experimental Therapeutics at Sylvester Comprehensive Cancer Center, shared a post on LinkedIn:
“Thank you, EHA25, for inviting me to present our results from the randomized, multicenter ADVANCE clinical trial for the treatment of patients with newly diagnosed multiple myeloma – at the annual meeting in Milan, Italy!
The study shows that the 4-drug combination with Daratumumab-Carfilzomib-Lenalidomide-dexamethasone (Dara-KRd) delivers significantly (p<0.0001; OR=2.9) higher MRD negativity rates compared to KRd. The results are consistent across subgroups.
The progression-free survival analysis shows that at almost 3 years of follow-up, 92% of the patients treated with Dara-KRd) are are doing well and are free from progression. The study was open for enrollment, independent of transplant eligibility (transplant eligible, transplant ineligible, and transplant deferred). MRD negativity after 8 cycles of combination therapy was the primary endpoint. There were no new safety signals.
We conclude that Dara-KRd is a new standard of care for newly diagnosed multiple myeloma patients, independent of transplant eligibility.
Thank you to all patients and family who participated in the ADVANCE clinical trial for newly diagnosed multiple myeloma! Thank you to all our collaborators and thank you to our funding support!”
More posts from EHA 2025.
-
Jun 19, 2025, 03:39ASH Recognizes 11 Hematologists for Transformative Contributions to Blood Disorder Research
-
Jun 17, 2025, 10:3025 Posts Not to Miss from EHA 2025
-
Jun 17, 2025, 05:10Recombinant ADAMTS13 Shows Superior Efficacy Over Plasma in Congenital TTP: A Paradigm Shift in Replacement Therapy - Blood Journals Portfolio
-
Jun 16, 2025, 17:00Hypoxia and Emergency Caesarean Deliveries Worsen Postpartum Outcomes in Sickle Cell Disease: New Insights from Perinatal Hemostasis Research
-
Jun 16, 2025, 10:42Jorge Cortes: The First Issue of Blood Global Hematology is Out
-
Jun 18, 2025, 15:49Abdul Mannan: Laboratory Alert - DOAC Interference in Heparin Monitoring
-
Jun 18, 2025, 08:19William Aird: Thrombocytosis - Know the difference, think before you refer
-
Jun 16, 2025, 18:24Talha Badar: TKI Selection Based on Mutation Profiles in CML at EHA 2025
-
Jun 16, 2025, 16:24Yelak Biru: Anito-Cel Drives Durable Responses in R/R Multiple Myeloma
-
Jun 15, 2025, 09:32Silent Threat: Underrated Risk of Thrombosis in IBD Outpatients Revealed by New Data - Thrombosis Update
-
Mar 6, 2025, 17:15Olympus Announces Launch of Single-Use Hemostasis Clip
-
Jun 18, 2025, 10:30Join "Where Cardiologists and Hematologists Meet" Session Organized by ESC and EHA
-
Jun 18, 2025, 09:01Nihar Desai: A 35 Year Old Man Presents with High Grade Fever...
-
Jun 17, 2025, 18:38Anastasia Conti: The European Hematology Association Congress Was Amazing
-
Jun 17, 2025, 17:07Mark Wildgust: Outstanding Results from the FLAIR Study Presented at EHA25
-
Jun 17, 2025, 15:03Hamayak Sisakian Announces ESC Heart Failure Center Accreditation
Jun 18, 2025, 15:49
Jun 18, 2025, 10:50
Jun 18, 2025, 09:01
Jun 18, 2025, 08:19
Jun 17, 2025, 18:38
Jun 17, 2025, 17:07
Jun 17, 2025, 15:03
Jun 17, 2025, 10:30
Jun 17, 2025, 06:55